Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs.

The authors discuss the steps that should be considered by insurers, payers and policy makers to support and achieve a value-based pricing system for drugs. Topics include Medicare, the U.S. Food and Drug Administration (FDA), and the Institute for Clinical and Economic Review (ICER) and policies preventing the ability of the Medicare to apply a value-based pricing system.